Clinical trial
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung…
NCT00147537 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00147537 |
|---|---|
| Title | Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer |
| Official title | A Phase 1b Dose Escalation/Phase 2 Randomized, Non-Comparative, Multiple Center, Open Label Study Of CP 751,871 In Combination With Paclitaxel And Carboplatin And Of Paclitaxel And Carboplatin Alone As First Line Treatment For Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | CP-751, 871, paclitaxel, carboplatin, erlotinib |
| Enrollment | 282 |
| Start date | Feb 1, 2005 |
| Primary completion | Aug 1, 2011 |
| Completion | Aug 1, 2011 |
| First posted | Sep 7, 2005 |
| Last update posted | Oct 30, 2013 |
| Countries | Canada, Italy, Spain, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: